Despite changes in guideline-based management of moderate/severe traumatic brain injury
(TBI) over the preceding decades, little impact on mortality and morbidity have been seen …

Traumatic brain injury remains a leading cause of death and disability across the globe.
Substantial uncertainty in outcome prediction continues to be the rule notwithstanding the …

Multi-modal biomarkers (eg, imaging, blood-based, physiological) of unique traumatic brain
injury (TBI) endophenotypes are necessary to guide the development of personalized and …

Severe traumatic brain injury (TBI) represents a major cause of neurological mortality and
morbidity throughout the world. Several challenges have been faced in the conduct of …

Traumatic brain injury (TBI) is a growing global problem, which is responsible for a
substantial burden of disability and death, and which generates substantial healthcare costs …

Throughout the past few decades, the ability to treat and rehabilitate traumatic brain injury
(TBI) patients has become critically reliant upon the use of neuroimaging to acquire …

Neuroproteomics, an emerging field at the intersection of neuroscience and proteomics, has
garnered significant attention in the context of neurotrauma research. Neuroproteomics …

Recent biomarker innovations hold potential for transforming diagnosis, prognostic
modeling, and precision therapeutic targeting of traumatic brain injury (TBI). However, many …

The heterogeneity of traumatic brain injury (TBI) remains a core challenge for the success of
interventional clinical trials. Data-driven approaches for patient stratification may help to …

It is widely appreciated that the spectrum of traumatic brain injury (TBI), mild through severe,
contains distinct clinical presentations, variably referred to as subtypes, phenotypes, and/or …